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ABSTRACT
Thyroid hormone has been shown to stimulate bone résorption. Both endogenous hyperthyroidism and exogenous
thyroxine suppressive therapy have been associated with reduction in bone mineral density (BMD), but the
patholophysiology of thyroxine-induced bone loss is not well understood. First we studied the effect of L-T4 (0.1-0.3
u,g/g body weight ip/day) on bone turnover in rats by measuring regional BMDs and osteocalcin mRNA. Next we
determined whether antiresorptive agents (calcitonin 1 |xU/g ip/day or sodium etidronate given cyclically at 10 u.g/g po
for 3 consecutive days out of every week) could prevent bone loss. Groups of 10 male Sprague-Dawley rats each
weighing 320-350 g were studied before and after 3 weeks of treatment. L-T4 treatment resulted in reduction in BMDs
in the lumbar spine, tail, and femur as measured by dual energy X-ray absorptiometry, but there was no correlation
with the dosage of L-T4 or the serum T4 level. Treatment with sodium etidronate or calcitonin alone did not alter the
regional BMD. Cyclical sodium etidronate, but not calcitonin, was able to prevent the bone loss induced by L-T4
treatment. L-T4 caused a dose-dependent increase in femur osteocalcin mRNA concentration. Treatment with
calcitonin resulted in 50% reduction of osteocalcin mRNA, but sodium etidronate had no effect. In conclusion,
cyclical sodium etidronate prevents bone loss induced by exogenous L-T4 in rats and may be useful in preventing
osteoporosis in patients given long term TSH-suppressive doses of thyroxine therapy.
INTRODUCTION
THYROID HORMONES have been shown to regulate normalbone maturation, as evidenced by the fact that hyperthy-
roidism or hypothyroidism in childhood is associated with
abnormal growth and stature (1,2). In adults, recent evidence
shows that an excess of thyroid hormones affects the remodeling
system in cortical and trabecular bone and may contribute to the
development of osteoporosis (3). Thyroid hormone increases
calcium release from fetal rat long bone cultures and increases
osteoblast number and activity (4). In vivo, thyroid hormone
also stimulates osteoblast activity (5). In hyperthyroidism the
activation frequency of bone remodeling is increased, which
results in an accelerated bone résorption and a concomitant
increase in bone formation, with a marked shortening of both
resorptive and formative phases of the remodeling cycle (6).
This results in a net reduction ofbone mass. A number of studies
confirmed that patients suffering from hyperthyroidism had lower
bone mineral content at both cortical and trabecular bone (7).
Furthermore, decrease in bone mineral densities (BMD) was
similarly observed in subjects on physiologic or suppressive dos-
age ofL-thyroxine treatment in some studies but not in others (8,9).
It is still debatable whether adjunctive therapy is warranted to
prevent rapid bone loss during thyroxine therapy, especially in
postmenopausal women and older individuals who present with
symptomatic or severe bone loss. Antiresorptive agents such as
calcitonin and the diphosphonates that act by inhibiting osteo-
clast activity have been shown to prevent bone loss in patients
with postmenopausal osteoporosis (10-13). The present study
describes an animal model of thyroxine-induced bone loss and
investigates whether these antiresorptive agents could prevent
the decrease in BMD.
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MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats of 8-10 weeks (320-350 g body
weight) were chosen for study. They were housed in a room with
controlled temperature (22 ± 1°C) and humidity (65-70%).
They were fed with normal diet (Ralston Purina) and allowed
free access to tap water.
Experimental design
Groups of 10 rats each were treated for 3 weeks accordingly.
Control rats received daily intraperitoneal (ip) injection of
normal saline. Hyperthyroidism was induced by giving levothy-
roxine (L-T4, Sigma Chemical Co.) at doses of 0.1-0.3 mg/kg
body weight ip daily, and hypothyroidism was induced by
giving propylthiouracil (Sigma) as 0.1% (w/v) solution per os
(po). As for antiresorptive therapy, salmon calcitonin (Miacal-
cic, Sandoz Pharmaceutical, Switzerland) was given at 1 U/kg
ip daily, and disodium etidronate (Didronel, Norwich Eaten,
Austria) was given cyclically at a dose of 10 mg/kg po for 3
consecutive days per week. The dosage and regimen of the
antiresorptive therapy were similar to those applied to human
studies.
Bone mineral density measurement
Animals were anesthetized with sodium pentobarbital (Ab-
bott), 50 mg/kg injected ip and did not move during scanning.
Total body and regional bone mineral densities (BMD) were
measured by the small animal scan program of Norland XR-26
bone densitometer (Fort Atkinson, Wisconsin), which is oper-
ated by the principle of dual energy X-ray absorptiometry (14).
The accuracy and precision ofestimating BMD in total animal in
vivo were found to be 1%. An ultrastable X-ray source, operated
at 100 kV and 1 mA, was used to provide the X-ray beam that
was then K-edged (46.8 keV) by the samarium filtering module.
This resulted in production of monochromatic X-ray beams with
two energies at approximately 45 and 80 keV. The dual energy
beam was then scanned rectilinearly over the region of interest.
The BMD was measured on a pixel-by-pixel basis and was
calculated by a series of given iterations with an IBM PS-2
computer. The specially designed collimator and a special
software were incorporated for the scanning of small animals.
Bone scans were done on each animal for the total body, lumbar
spine, tail, and right femoral region (Fig. 1). Regional BMDs
were performed within a fixed area to assist in repeatable
placement of cursors on follow-up scans. Bone densities were
measured before and after 3 weeks of treatment. The whole set
of experiment was carried out 3 times, each time with the same
experimental design.
RNA extraction and hybridization
Rat femur was snap frozen in liquid nitrogen and RNA was
extracted with guanidinium thiocyanate immediately after the
muscle and periosteum were removed. The single step acid
guanidinium-phenol-chloroform method was used to isolate the
total cellular RNA (15). An oligonucleotide (5'-AGAGA-
FIG. 1. Bone scan of the rat as determined by dual energy X-ray
absorptiometry.
GAGGGTCCTCATGGT-3') was synthesized corresponding to
the complementary sequences of the bases 1-20 of the rat
osteocalcin cDNA (16). The oligonucleotide probe was 5'
end-labeled with [-y-32-P]ATP and T4 polynucleotide kinase(Promega Corporation, Madison, WI). Hybridization was car-
ried out overnight in 5 x SSC (0.3 M sodium chloride-0.03 M
sodium citrate), 20 mM phosphate pH 7.0, 10 x Denhardt
solution, 7% sodium dodecyl sulfate (SDS), and 10% dextran
sulfate at 62°C. Washing of the membrane was performed in
3 x SSC, 25 mM P04, pH 7.5, 10 x Denhardt solution, 5%
SDS for 1 h at 57°C and then one wash in 1 x SSC, 1% SDS.
The size of the rat osteocalcin mRNA was previously deter-
mined to be approximately 0.6 kb. The hybridization signal was
ascertained by scanning densitometry in an LKB instrument
(Rockville, MD). The amount of total RNA loaded per lane was
normalized to the amount of 28 S RNA, which was determined
by staining the membrane with méthylène blue.
Thyroid function
Blood was collected at termination of the experiment by
cardiac puncture, and sera were stored at —20°C until batch
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Table 1. Thyroid Function Tests of the Rats"
Group Serum T4 (\i-gldL) TSH (nglmL)
Control
T40.1 mg/kg
T4 0.2 mg/kg
T4 0.3 mg/kg
Propylthiouracil
5.5 ± 1.2
8.7 ± 2.3*
16.2 ± 3.6*
20.8 ± 6.9*
<1.0*
0.43 ± 0.26
<0.05*
<0.05*
<0.05*
3.6 ± 0.65*
"Results are mean ± SD; n = 10 in each group.
*p < 0.05 vs control.
assay. Serum T4 and TSH levels were measured by radioimmu-
noassay. Tracer and antibodies were obtained from ICN Bio-
medicals Inc. (Costa Mesa, CA).
Statistics
Comparison between groups was analyzed by one-way anal-
ysis of variance, and p < 0.05 was considered as significant.
Spearman's rank correlation was used to determine the relation
between the dose and duration of L-T4 treatment with the
regional BMDs.
RESULTS
Effect ofL-T4 on BMD
At baseline, all groups had similar body weight, total body
bone mineral content (BMC), and regional BMDs. The mean
total body BMC was 9.406 ± 0.216 (SD) g, femur BMD was
0.117 ± 0.002 g/cm2, spine BMD was 0.113 ± 0.003 g/cm2,
and tail BMD was 0.106 ± 0.004 g/cm2. After 3 weeks, body
weight increased by 30% from 330 ± 15 g to 437 ± 95 g in the
control rats. Total body BMC also increased by 11% to
10.478 ± 0.263 g. There was no significant change in linear
growth (week 0, 24.69 ± 0.80 cm versus week 3,
25.80 ± 0.56 cm). L-T4 treatment caused a dose-dependent
elevation in the serum total T4 level (Table 1). All hyperthyroid
rats had unmeasurable TSH levels. L-T4 treatment resulted in
significant reduction in BMDs of the lumbar spine, tail, and
femur (Table 2). However, there was no correlation between the
regional BMDs and the dosage of L-T4 treatment or the serum T4
level. Propylthiouracil treatment reduced serum T4 level and
also caused a significant decrease in body weight. A reduction in
total body mineral content was seen but there was no significant
change in the regional BMDs in these hypothyroid rats. How-
ever, when the results were adjusted for the body weight in these
hypothyroid rats, the total body BMC as well as the BMDs of the
femoral and lumbar spine but not the tail were significantly
higher than the control rats [total body BMC, 28.17 ± 2.73 vs
23.12 ± 0.72 g/kg body weight (BW), p < 0.05; femur BMD,
0.382 ± 0.028 vs 0.316 ± 0.020 g/cm2/kg BW, p < 0.05;
spine BMD, 0.455 ± 0.055 vs 0.332 ± 0.020 g/cm2/kg BW,
p < 0.05; tail BMD, 0.299 ± 0.014 vs 0.265 ± 0.029
g/cm2/kg BW, p = NS, respectively].
Effects of antiresorptive agent in BMDs
L-T4 0.3 mg/kg BW was chosen to study the effect of
calcitonin and sodium etidronate on regional BMDs. Both
sodium etidronate and calcitonin alone had no effect on regional
BMDs. After treatment for 3 weeks, cyclical sodium etidronate
treatment was able to prevent the reduction in BMDs induced by
L-T4 treatment (Table 3). Although rats treated with L-T4 and
calcitonin had higher regional BMDs compared with L-T4
treatment alone (p = NS), they still had lower BMDs when
compared with controls (p < 0.05).
Osteocalcin mRNA
L-T4 treatment caused a dose-dependent increase in femur
osteocalcin mRNA concentration when compared with controls
Table 2A. Bone Density in Hyperthyroid and Hypothyroid Rats"
Group BW(g) Total body BMC (g) Femur BMD (g/cm2) Spine BMD (g/cm2) Tail BMD (g/cm2)
Control
T40.1 mg/kg
T4 0.2 mg/kg
T4 0.3 mg/kg
Propylthiouracil
437 ± 95
427 ± 83
431 ±54
420 ± 68
407 ± 88*
10.478
10.450
10.279
10.391
0.263
0.395
0.299
0.278
10.006 ± 0.069*
0.137 ±0.007
0.124 ±0.004*
0.121 ±0.004*
0.119 ±0.008*
0.136 ±0.009
0.144 ±0.009
0.126 ± 0.006*
0.123 ±0.010*
0.122 ±0.010*
0.148 ±0.010
0.124 ±0.007
0.118 ±0.006*
0.114 ± 0.005*
0.115 ±0.008*
0.120 ±0.010
"Results are mean ± SD: n = 10 in each group.
*p < 0.05 vs control.
Table 2B. Bone Density of Hypothyroid Rats after Adjustment for Body Weight0
TBMC"/weight(g/kg)
Femur BMD/weight(glcnflkg) Spine BMD/weight(g/cm2/kg) Tail BMD/weight(glcm2lkg)
Hypothyroidism
Control
28.17 ± 2.73*
23.12 ± 0.72
0.382 ± 0.028*
0.316 ±0.020
0.455 ± 0.055*
0.332 ± 0.020
0.299
0.265
0.014
0.029
"Results are mean ± SD.
*TBMC, total body bone mineral content.
*p < 0.05.
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Group
Table 3. Effect of Anti Resportive Agent of Regional BMDs"
Femur BMD (g/cm2) Spine BMD (g/cm2) Tail BMD (g/cm2)
Control
T4 0.3 mg/kg
T4 + sodium etidronate
T4 + calcitonin
Sodium etidronate
Calcitonin
0.137 ±0.007
0.119 ±0.008*
0.131 ±0.006
0.123 ± 0.005*
0.140 ±0.008
0.138 ±0.008
0.144 ± 0.007
0.122 ± 0.010*
0.143 ± 0.010
0.131 ±0.007*
0.142 ±0.009
0.142 ±0.006
0.124 ±0.007
0.115 ±0.008*
0.119 ±0.008
0.112 ±0.007*
0.126 ±0.006
0.123 ±0.009
"Results are mean ± SD.
*p < 0.05 vs control.
(Fig. 2). The densitometric results for T4 0.1, 0.2, and 0.3
mg/kg were 110 ± 6,129 ± 15, and 175 ± 20% ofthe control,
respectively. In the hypothyroid rat osteocalcin mRNA concen-
tration was reduced to 40 ± 10% of the control. Treatment with
calcitonin reduced osteocalcin mRNA to 50% of the control,
whereas disodium etidronate did not affect osteocalcin gene
expression. Treatment of the rats with both L-T4 0.3 mg/kg and
calcitonin resulted in a steady state osteocalcin mRNA concen-
tration of about 70% of the control (Table 4).
DISCUSSION
Our present data demonstrated that in rats exogenous thyroid
hormone produced bone loss in the spine and femoral bones
simulating its action in humans. Using the rat model for studies
of bone metabolism is well documented, and models of human
pathologies like aging (17), estrogen depletion (18), immobili-
zation (19), and dietary calcium deficiency (20) have been
established. The use of a noninvasive technique such as DEXA
0-6 kb-^ i fw W w
for determination of BMD has also been varified in rats, with
data correlating strongly with those obtained by ashing (21,22).
The pattern of bone loss in this rat model is similar to that
observed in humans. It has been reported that thyroid hormone
induced bone loss in appendicular bone in premenopausal
women (23), while in postmenopausal subjects bone loss is
observed in both appendicular and axial bone (24). The overall
pattern of bone loss induced by exogenous thyroid hormone
therapy is similar to that observed in patients with endogenous
hyperthyroidism (25). Ongphiphadhanakul et al performed sim-
ilar study and demonstrated that excessive L-T4 therapy induced
bone loss in the rat femur, except that they did not observe any
change in the rat spine (26).
The pharmacopathology of thyroid hormone-induced bone
loss is not well understood. Although both T3 and T4 dose
dependently stimulate 45Ca release from cultured fetal rat long
bones in vitro (4), the effect is biphasic in mouse; higher doses
of T3 inhibit rather than stimulate calcium release (27). We
observed that in patients on physiologic dose of L-T4 replace-
ment with normal thyroid function, the Z score of the femoral
neck correlated negatively with the serum-free thyroxine index(FTI) (8), whereas in patients on L-T4 suppressive therapy with
elevated serum FTI, no correlation was observed between the
serum thyroid function and the regional BMD values or their Z
scores. This was also observed in our present hyperthyroid rat
model, but the degree of bone loss did not correlate with the dose
of L-T4 given or the serum thyroid hormone level. Whether
thyroid hormone also affects other growth factors that modulate
bone remodeling awaits further confirmation. In the present
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FIG. 2. Effect of thyroid hormone on osteocalcin mRNA level.
Table 4.
Group
Effect of LT4 and Antiresorptive Agents on
Osteocalcin mRNA"
Densitometric unit (%)
Control
T40.1 mg/kg BW
T4 0.2 mg/kg BW
T4 0.3 mg/kg BW
Calcitonin
T4 0.3 mg/kg + calcitonin
Sodium etidronate
T4 0.3 mg/kg + sodium etidronate
"Results are mean ± SD.
*p < 0.05 vs control.
100
110± 6
129 ± 15*
175 ± 20*
50 ± 10*
70 ± 15
90 ± 20
158 ± 16*
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study we also observed that in the hypothyroid rats, the adjusted
regional BMDs were higher than controls. This finding has been
reported in humans (28).
Thyroid hormone exerts its bone résorption activity via its
action on the osteoblasts. Nuclear thyroid hormone receptors
have been identified in rat osteosarcoma cell lines UMR-106
(29) and mouse osteoblast-like cell line MC3 T3-E1 (30). Also,
human osteoblastic cell line MG63 has been shown to express T3
receptor mRNA (31). Thyroid hormone receptors have not been
identified in osteoclasts and there was no effect of T3 on bone
résorption by isolated osteoclasts (30). It is thus believed that the
effect of thyroid hormone on osteoclastic bone résorption is
indirectly mediated, and the osteoblast acts as the intermediary
cell, thus resulting in a high turnover bone loss.
In this present rat model, we observed a positive relationship
between serum T4 level and osteocalcin mRNA expression. This
finding has also been reported previously (32). Osteocalcin is a
noncollagenous bone matrix protein synthesized by osteoblasts
and has been a useful clinical marker for increased bone
turnover (33). Serum osteocalcin is increased in hyperthyroid
patients (34) and in patients with multinodular goitre with
suppressed TSH levels (35). We also observed in patients on
long-term L-T4 suppressive therapy with elevated serum osteo-
calcin level, there was a negative correlation between the serum
osteocalcin and the Z score of the regional BMDs (9). Thus
estimation of osteocalcin may be a sensitive way of identifying
which patient is at particular high risk of developing osteoporo-
sis. However, our study has not addressed how thyroid hormone
increases steady-state osteocalcin mRNA. Osteocalcin tran-
scription is stimulated by l,25-(OH)2 D3 (36), but thyroid
hormone has not been shown to increase osteocalcin transcrip-
tion in transfection studies (37). The action of thyroid hormone
probably does not depend on vitamin D as hyperthyroidism is
associated with a reduction in 1,25-(OH)2 D3 levels both in man
(38) and rats (39).
In this study we also examined the protective effect of
antiresorptive agents against L-T4-induced bone loss. The
diphosphonate agent, sodium etidronate, but not calcitonin, was
able to prevent L-T4-induced bone loss both in the femoral and
spinal region. Interestingly, the increase in osteocalcin mRNA
expression induced by L-T4 was not altered by disodium
etidronate treatment but was reversed by calcitonin. The sup-
pressive effect of calcitonin is also reflected at the translational
level as Ongphiphadhanakul et al. reported a decrease in serum
osteocalcin level in rats treated with calcitonin (26). The
diphosphonates are nonbiodegradable analogues of pyrophos-
phate with a high binding affinity for hydroxyapatite crystals(40). They inhibit bone résorption by binding to bone surfaces
and cause injury to the osteoclasts. Calcitonin, on the other
hand, inhibits osteoclastic activity and motility ad reduces their
cell number (41). The effect of these agents on bone formation is
complex and it has not yet been established for certain whether
they exert any effect on the osteoblast. For example, studies of
the long-term effect of calcitonin on bone remodeling suggest
that it lengthens the formation phase at the expense of the
reversal phase between résorption and formation (42). This
might be due to an indirect effect via osteoclasts or to a direct
effect via osteoblasts. So far calcitonin receptor has only been
found in the osteoclast but not osteoblast (43). Thus the
observed inhibitory effect of calcitonin on osteocalcin gene
expression is probably via an intermediary effect on osteoclasts,
thus decreasing bone turnover. Although treatment of the
thyrotoxic rats with calcitonin negated the effect of thyroxine on
steady-state osteocalcin mRNA, the actions of L-T4 and calci-
tonin on osteocalcin gene transcription are probably at different
levels and require further elucidation. It is also of interest that
despite the effectiveness of sodium etidronate in preventing
bone loss, it has no effect on L-T4-induced elevation of osteo-
calcin mRNA concentration. Ongphiphadehanakul similarly
reported that sodium etidronate was able to prevent the bone loss
but not the increase in tartrate-resistant acid phosphatase in-
duced by L-T4 (44).
Both calcitonin and sodium etidronate have been proven to be
effective in the treatment of postmenopausal osteoporosis
(10-13). Thus it was surprising to observe in this study that
calcitonin is ineffective in preventing bone loss induced by
L-T4, as calcitonin has in fact been demonstrated to be more
effective in those osteoporotic patients with "high" turnover
than in those with "low" turnover, as defined biochemically by
an elevation of osteocalcin (45). The use of calcitonin in
treatment high turnover bone loss is well illustrated by its
effectiveness in treating Paget's disease (46). Thus, the role of
antiresorptive agents in preventing thyroid hormone induced
bone loss needs to be confirmed in human studies.
In conclusion, we have established a rat model of thyroid
hormone induced bone loss. The diphosphonate agent, sodium
etidronate, but not calcitonin, was able to prevent L-T4-induced
bone loss in the present model.
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